Health Care • Biotechnology: Pharmaceutical Preparations
$15.95 ▲ +0.22
(+1.40%)
MKT CAP: $786.5M • VOL: 658.3K
52W L $11 52W H $36
ROARABLE / RQD
D- • 35/100
PIOTROSKI
2 / 9
AVBP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$177.5M | -$94.3M | -$74.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$166.3M | -$80.5M | -$69.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$160.6M | -$70.2M | -$55.8M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$160.6M | -$70.2M | -$55.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -40.6% | — |
| Cash & Short-Term Equivalents | $45.5M | $74.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $307.2M | $257.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AVBP.